Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082150 | 0.95 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL6060258 | 0.93 | LMNA (0.39) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL6060298 | 0.93 | LMNA (0.39) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL6060491 | 0.91 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6060613 | 0.91 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6060909 | 0.86 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL6060158 | 0.85 | GAA (0.33) | — | |
| SCHEMBL6059790 | 0.84 | LMNA (0.35) | LMNA | |
| SCHEMBL6060526 | 0.84 | LMNA (0.35) | LMNA | |
| SCHEMBL27524107 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071344-B1 | Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments | SCHERING AG (DE) | 2006-07-04 | — | — | US | disclosed |
| US-20050227951-A1 | Verification of translation | STEINMEYER ANDREAS | 2005-10-13 | — | — | US | disclosed |
| CN-1214006-C | Novel vitamin D derivatives with cyclopropyl rings in lateral chains, its production method and intermediate and utilization thereof for producing medicaments | SCHERING AG (DE) | 2005-08-10 | — | — | CN | disclosed |
| EP-1025082-B1 | NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | STEINMEYER ANDREAS (DE) | 2003-01-23 | — | — | US | disclosed |
| CN-1272840-A | Vitamin D derivatives with cyclopropyl ring in side chain, preparation method and intermediate products thereof and application in preparing medicines | SCHERING AG (DE) | 2000-11-08 | — | — | CN | disclosed |
| EP-1025082-A1 | NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999016745-A1 | NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227951-A1 | Verification of translation | CYP2R1, CYP24A1, VDR | ALDH1A1 780/4885SMN1; SMN2 3881/4885LMNA 3878/4885 |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | CYP2R1, CYP24A1, VDR | ALDH1A1 599/4885SMN1; SMN2 4873/4885LMNA 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.